Gastric Cancer Pharmacogenetics: Progress or Old Tripe?

• Nishiyama M , EguchiH. Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv. Drug. Deliv. Rev.61(5) , 402–407 (2009).
   PubMed Web of Science ®Google Scholar
• Crew KD , NeugutAI. Epidemiology of gastric cancer. World J. Gastroenterol.12(3) , 354–362 (2006).
   PubMed Web of Science ®Google Scholar
• MacDonald JS , SmalleySR, BenedettiJ et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10) , 725–730 (2001).
   PubMed Web of Science ®Google Scholar
• Cullinan SA , MoertelCG, WieandHS et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J. Clin. Oncol. 12(2) , 412–416 (1994).
   PubMed Web of Science ®Google Scholar
• Webb A , CunninghamD, ScarffeJH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15(1) , 261–267 (1997).
   PubMed Web of Science ®Google Scholar
• Bouche O , RaoulJL, BonnetainF et al. Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study – FFCD 9803. J. Clin. Oncol. 22(21) , 4319–4328 (2004).
   PubMed Web of Science ®Google Scholar
• Wang F , WangZ, ZhouN et al. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Am. J. Clin. Oncol. 34(4) , 401–405 (2011).
   PubMed Web of Science ®Google Scholar
• Fuchs C , TepperJ, NiedzwieckiD, HollisD, MamonH. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional 5-FU (ECF) before and after infusion 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J. Clin. Oncol. Suppl. (2011) (Abstract 4003).
   Google Scholar
• Cunningham D , StarlingN, RaoS et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358(1) , 36–46 (2008).
   PubMed Web of Science ®Google Scholar
• Kulke MH , WuB, ClarkJW et al. A Phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest. 24(3) , 229–234 (2006).
   PubMed Web of Science ®Google Scholar
• Kang YK , KangWK, ShinDB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol. 20(4) , 666–673 (2009).
   PubMed Web of Science ®Google Scholar
• Popov I , Radosevic-JelicL, JezdicS et al. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. J. BUON 13(4) , 505–511 (2008).
   PubMed Web of Science ®Google Scholar
• Li ZY , KohCE, BuZD et al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J. Surg. Oncol. 105(8) , 793–799 (2012).
   PubMed Web of Science ®Google Scholar
• Kawakami K , GrazianoF, WatanabeG et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin. Cancer Res. 11(10) , 3778–3783 (2005).
   PubMed Web of Science ®Google Scholar
• Shitara K , MuroK, ItoS et al. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer. Cancer Epidemiol. Biomark. Prev. 19(5) , 1311–1319 (2010).
   PubMed Web of Science ®Google Scholar
• Marsh S , McKayJA, CassidyJ, McLeodHL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol.19(2) , 383–386 (2001).
   PubMed Web of Science ®Google Scholar
• Thomas F , HoskinsJM, DvorakA, TanBR, McLeodHL. Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. Pharmacogenomics11(12) , 1751–1756 (2010).
   PubMed Web of Science ®Google Scholar
• Villafranca E , OkruzhnovY, DominguezMA et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19(6) , 1779–1786 (2001).
   PubMed Web of Science ®Google Scholar
• Ruzzo A , GrazianoF, KawakamiK et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J. Clin. Oncol. 24(12) , 1883–1891 (2006).
   PubMed Web of Science ®Google Scholar
• Tan BR , ThomasF, MyersonRJ et al. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J. Clin. Oncol. 29(7) , 875–883 (2011).
   PubMed Web of Science ®Google Scholar
• Toffoli G , CecchinE. Pharmacogenetics and stomach cancer: an update. Pharmacogenomics8(5) , 497–505 (2007).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB , MeinsmaR, ZoetekouwL, Van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics12(7) , 555–558 (2002).
   PubMedGoogle Scholar
• Saif MW , DiasioR. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin. Colorectal Cancer5(5) , 359–362 (2006).
   PubMed Web of Science ®Google Scholar
• Yen JL , McLeodHL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur. J. Cancer43(6) , 1011–1016 (2007).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB , HaasjesJ, RichelDJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6(12) , 4705–4712 (2000).
   PubMed Web of Science ®Google Scholar
• Mattison LK , FourieJ, DesmondRA, ModakA, SaifMW, DiasioRB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African–Americans compared with Caucasians. Clin. Cancer Res.12(18) , 5491–5495 (2006).
   PubMed Web of Science ®Google Scholar
• De Mattia E , ToffoliG. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur. J. Cancer45(8) , 1333–1351 (2009).
   PubMed Web of Science ®Google Scholar
• Wilcken B , BamforthF, LiZ et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J. Med. Genet. 40(8) , 619–625 (2003).
   PubMed Web of Science ®Google Scholar
• Lu JW , GaoCM, WuJZ, SunXF, WangL, FengJF. Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma. Ai Zheng23(8) , 958–962 (2004).
   PubMedGoogle Scholar
• Ott K , VogelsangH, MartonN et al. The thymidylate synthase tandem repeat promoter polymorphism: a predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int. J. Cancer 119(12) , 2885–2894 (2006).
   PubMed Web of Science ®Google Scholar
• Shim HJ , YunJY, HwangJE et al. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci.101(5) , 1247–1254 (2010).
   PubMed Web of Science ®Google Scholar
• Goekkurt E , Al-BatranSE, HartmannJT et al. Pharmacogenetic analyses of a Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J. Clin. Oncol. 27(17) , 2863–2873 (2009).
   PubMed Web of Science ®Google Scholar
• Ulrich CM , BiglerJ, BostickR, FosdickL, PotterJD. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res.62(12) , 3361–3364 (2002).
   PubMed Web of Science ®Google Scholar
• Largillier R , Etienne-GrimaldiMC, FormentoJL et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res. 12(18) , 5496–5502 (2006).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB . Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer40(7) , 939–950 (2004).
   PubMed Web of Science ®Google Scholar
• Caronia D , MartinM, SastreJ et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand–foot syndrome. Clin. Cancer Res. 17(7) , 2006–2013 (2011).
   PubMed Web of Science ®Google Scholar
• Park SR , KongSY, NamBH et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br. J. Cancer104(7) , 1126–1134 (2011).
   PubMed Web of Science ®Google Scholar
• Yen-Revollo JL , GoldbergRM, McLeodHL. Can inhibiting dihydropyrimidine dehydrogenase limit hand–foot syndrome caused by fluoropyrimidines? Clin. Cancer Res.14(1) , 8–13 (2008).
   PubMed Web of Science ®Google Scholar
• Fujita K , YamamotoW, EndoS et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci.99(5) , 1049–1054 (2008).
   PubMed Web of Science ®Google Scholar
• Goekkurt E , HoehnS, WolschkeC et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) – novel predictors for response and survival in gastric cancer patients. Br. J. Cancer 94(2) , 281–286 (2006).
   PubMed Web of Science ®Google Scholar
• Bradbury PA , KulkeMH, HeistRS et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet. Genomics 19(8) , 613–625 (2009).
   PubMed Web of Science ®Google Scholar
• Buchanan CC , TorstensonES, BushWS, RitchieMD. A comparison of cataloged variation between International HapMap Consortium and 1000 Genomes Project data. J. Am. Med. Inform. Assoc.19(2) , 289–294 (2012).
   PubMed Web of Science ®Google Scholar
• Tse D , ZhaiR, ZhouW et al. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control 19(10) , 1077–1083 (2008).
   PubMed Web of Science ®Google Scholar
• Innocenti F , LiuW, FackenthalD et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet. Genomics 18(8) , 683–697 (2008).
   PubMed Web of Science ®Google Scholar
• Parmar S , StinglJC, Huber-WechselbergerA et al. Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Res. 13(3) , R57 (2011).
   PubMed Web of Science ®Google Scholar
• Gehrmann M , SchmidtM, BraseJC, RoosP, HengstlerJG. Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence? Pharmacogenomics9(7) , 969–974 (2008).
   PubMed Web of Science ®Google Scholar
• Marsh S , SomloG, LiX et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7(5) , 362–365 (2007).
   PubMed Web of Science ®Google Scholar
• Dai D , ZeldinDC, BlaisdellJA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7) , 597–607 (2001).
   PubMedGoogle Scholar
• Leskela S , JaraC, Leandro-GarciaLJ et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 11(2) , 121–129 (2011).
   PubMed Web of Science ®Google Scholar
• Chang H , RhaSY, JeungHC et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann. Oncol. 20(2) , 272–277 (2009).
   PubMed Web of Science ®Google Scholar
• Chang H , RhaSY, JeungHC et al. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol. Rep. 23(1) , 271–278 (2010).
   PubMed Web of Science ®Google Scholar
• Perera MA , InnocentiF, RatainMJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy28(6) , 755–768 (2008).
   PubMed Web of Science ®Google Scholar
• Satoh T , UraT, YamadaY et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci. 102(10) , 1868–1873 (2011).
   PubMed Web of Science ®Google Scholar
• Wang Y , ShenL, XuN et al. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J. Gastroenterol.18(45) , 6635–6644 (2012).
   PubMed Web of Science ®Google Scholar
• Hoskins JM , GoldbergRM, QuP, IbrahimJG, McLeodHL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst.99(17) , 1290–1295 (2007).
   PubMedGoogle Scholar
• Marcuello E , PaezD, PareL et al. A genotype-directed Phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br. J. Cancer 105(1) , 53–57 (2011).
   PubMed Web of Science ®Google Scholar
• Jo JC , LeeJL, RyuMH et al. Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. Br. J. Cancer 106(10) , 1591–1597 (2012).
   PubMed Web of Science ®Google Scholar
• Font A , SalazarR, MaurelJ et al. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a Phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer Chemother. Pharmacol. 62(6) , 1075–1083 (2008).
   PubMed Web of Science ®Google Scholar
• Park SR , KongSY, RheeJ et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann. Oncol. 22(4) , 890–896 (2011).
   PubMed Web of Science ®Google Scholar
• Field K , MichaelM, LeongT. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs68(3) , 299–317 (2008).
   PubMed Web of Science ®Google Scholar
• Ross P , NicolsonM, CunninghamD et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. [see comment]. J. Clin. Oncol. 20(8) , 1996–2004 (2002).
   PubMed Web of Science ®Google Scholar
• Webb A , CunninghamD, ScarffeJH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. [see comment]. J. Clin. Oncol. 15(1) , 261–267 (1997).
   PubMed Web of Science ®Google Scholar
• Ajani JA , Van Custem E, Moiseyenko FC. Docetaxel (D), cisplatin, 5-fluorouracil compared with cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma: interim results of a randomized Phase III trial (V 325). Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 999).
   Google Scholar
• Ridwelski K , GebauerT, FahlkeJ et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann. Oncol. 12(1) , 47–51 (2001).
   PubMed Web of Science ®Google Scholar
• Roth AD , MaibachR, MartinelliG et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann. Oncol. 11(3) , 301–306 (2000).
   PubMed Web of Science ®Google Scholar
• Kim YH , ShinSW, KimBS et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85(2) , 295–301 (1999).
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C , QuietzschD, HaagC et al. A Phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br. J. Cancer 83(4) , 458–462 (2000).
   PubMed Web of Science ®Google Scholar
• Ajani JA , BakerJ, PistersPW et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) 16(5 Suppl. 5) , S16–S18 (2002).
   PubMed Web of Science ®Google Scholar
• Boku N , OhtsuA, ShimadaY et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 17(1) , 319–323 (1999).
   PubMed Web of Science ®Google Scholar
• Lim WT , LimST, WongNS, KooWH. CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians. J. Chemother.15(4) , 400–405 (2003).
   PubMed Web of Science ®Google Scholar
• Pozzo C , BugatR, PeschelC. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: final results of a randomized Phase II study. Proc. Am. Soc. Clin. Oncol.21 (2001) (Abstract 531a).
   Google Scholar
• Ohtsu A , ShimadaY, ShiraoK et al. Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. 21(1) , 54–59 (2003).
   PubMed Web of Science ®Google Scholar
• Dank M , ZaluskiJ, BaroneC et al. Randomized Phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. Proc. Am. Soc. Clin. Oncol. 24 (2005) (Abstract 4003).
   Google Scholar
• Al-Batran SE , AtmacaA, Hegewisch-BeckerS et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J. Clin. Oncol. 22(4) , 658–663 (2004).
   PubMed Web of Science ®Google Scholar
• de Vita F , OrdituraM, MatanoE et al. A Phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br. J. Cancer 92(9) , 1644–1649 (2005).
   PubMed Web of Science ®Google Scholar
• Kim DY , KimJH, LeeSH et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann. Oncol. 14(3) , 383–387 (2003).
   PubMed Web of Science ®Google Scholar
• Louvet C , AndreT, TigaudJM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 20(23) , 4543–4548 (2002).
   PubMed Web of Science ®Google Scholar
• Souglakos J , SyrigosK, PotamianouA et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre Phase II trial. Ann. Oncol. 15(8) , 1204–1209 (2004).
   PubMed Web of Science ®Google Scholar
• Koizumi W , TanabeS, AzumaM et al. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int. J. Cancer 126(1) , 162–170 (2010).
   PubMed Web of Science ®Google Scholar
• Lu JW , GaoCM, WuJZ, CaoHX, TajimaK, FengJF. Polymorphism in the 3´-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J. Hum. Genet.51(3) , 155–160 (2006).
   PubMed Web of Science ®Google Scholar
• Ichikawa W , TakahashiT, SutoK et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int. J. Cancer 119(8) , 1927–1933 (2006).
   PubMed Web of Science ®Google Scholar
• Fukuda H , TakiguchiN, KodaK, OdaK, SeikeK, MiyazakiM. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest.24(3) , 235–241 (2006).
   PubMed Web of Science ®Google Scholar
• Takiuchi H , KawabeS, GotohM, KatsuK. Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. Gastrointest. Cancer Res.1(5) , 171–176 (2007).
   PubMedGoogle Scholar
• Hua D , HuangZH, MaoY, DengJZ. Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J. Gastroenterol.13(37) , 5030–5034 (2007).
   PubMed Web of Science ®Google Scholar
• Seo BG , KwonHC, OhSY et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol. Rep. 22(1) , 127–136 (2009).
   PubMed Web of Science ®Google Scholar
• Kim SH , KwonHC, OhSY et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am. J. Clin. Oncol. 32(1) , 38–43 (2009).
   PubMed Web of Science ®Google Scholar
• Yeh CN , JungSM, ChenTW, HwangTL, JanYY, ChenMF. Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbeck‘s Arch. Surg.395(3) , 217–225 (2010).
   PubMed Web of Science ®Google Scholar
• Huang ZH , HuaD, LiLH. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Cancer Chem. Pharmacol.63(5) , 911–918 (2009).
   PubMed Web of Science ®Google Scholar
• Harpole DH Jr, Moore MB, Herndon JE 2nd et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res.7(3) , 562–569 (2001).
   PubMed Web of Science ®Google Scholar
• Cui YH , LiuTS, ZhuangRY et al. Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer. J. Dig Dis. 10(2) , 118–123 (2009).
   PubMed Web of Science ®Google Scholar
• Keam B , ImSA, HanSW et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 27(8) , 148–157 (2008).
   Google Scholar
• Jakobsen A , NielsenJN, GyldenkerneN et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol. 23(7) , 1365–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Han SW , OhDY, ImSA et al. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci. 101(3) , 793–799 (2010).
   PubMed Web of Science ®Google Scholar
• Toriumi F , KubotaT, SaikawaY et al. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res. 24(4) , 2455–2463 (2004).
   PubMed Web of Science ®Google Scholar
• Kwon HC , RohMS, OhSY et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol. 18(3) , 504–509 (2007).
   PubMed Web of Science ®Google Scholar
• Kim KH , KwonHC, OhSY et al. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers 16(1) , 74–82 (2011).
   PubMed Web of Science ®Google Scholar
• Peng RJ , DongQM, ShiYX et al. Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients. Ai Zheng 25(8) , 1039–1043 (2006).
   PubMedGoogle Scholar
• Zhang H , LiYM, ZhangH, JinX. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med. Oncol.24(2) , 251–258 (2007).
   PubMed Web of Science ®Google Scholar
• Matsubara J , NishinaT, YamadaY et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br. J. Cancer 98(4) , 832–839 (2008).
   PubMed Web of Science ®Google Scholar
• Grau JJ , CaballeroM, MonzoM et al. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J. Surg. Oncol. 98(2) , 130–134 (2008).
   PubMed Web of Science ®Google Scholar
• Koizumi W , OkayasuI, HyodoI, SakamotoJ, KojimaH, Clinical Study Group of C. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs19(8) , 819–824 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang XP , BaiZB, ChenBA et al. Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Chin. Med. J. 125(5) , 741–746 (2012).
   PubMed Web of Science ®Google Scholar
• Jeung HC , RhaSY, ShinSJ et al. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anticancer Drugs 22(8) , 801–810 (2011).
   PubMed Web of Science ®Google Scholar
• Amstutz U , FareseS, AebiS, LargiaderCR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics10(6) , 931–944 (2009).
   PubMed Web of Science ®Google Scholar
• Kong SY , LimHS, NamBH et al. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics 10(7) , 1147–1155 (2009).
   PubMed Web of Science ®Google Scholar
• Okuyama T , MaeharaY, EndoK et al. Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 74(4) , 1230–1236 (1994).
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J , ParkDJ, ZhangW et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl Cancer Inst. 94(12) , 936–942 (2002).
   PubMedGoogle Scholar
• Ott K , RachakondaPS, PanzramB et al. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann. Surg. Oncol. 18(9) , 2688–2698 (2011).
   PubMed Web of Science ®Google Scholar
• Warnecke-Eberz U , VallbohmerD, AlakusH et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J. Gastrointest. Surg.13(8) , 1411–1421 (2009).
   PubMed Web of Science ®Google Scholar
• Liu YP , LingY, ZhangYP, LiuBR. Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy. Zhonghua Yi Xue Za Zhi91(4) , 256–259 (2011).
   PubMedGoogle Scholar
• Shitara K , MatsuoK, ItoS et al. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac. J. Cancer Prev. 11(2) , 447–452 (2010).
   PubMedGoogle Scholar

▪ Websites

• US FDA: table of pharmacogenomic biomarkers in drug labels (2010). www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
   Google Scholar
• National Comprehensive CancerNetwork (NCCN) Guidelines Version 2.2012. Gastric Cancer (2012). www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
   Google Scholar